ReviewTranslational cancer research2025
The role of microRNAs in gastritis, intestinal metaplasia, and gastric cancer: a narrative review.
Review in Translational cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- MicroRNA-597 Suppresses Gastric Cancer Invasion and Progression viaInternational journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Objective: MicroRNAs (miRNAs or miRs) are critical epigenetic regulators in gastric carcinogenesis; however, to date, comprehensive analyses of their stage-specific dysregulation and clinical utility are limited. This review synthesized evidence on miRNA dysregulation throughout the gastritis-metaplasia-cancer cascade to assess the diagnostic and therapeutic potential of miRNAs. Research challenges are also discussed. Methods: A narrative overview was conducted based on systematic searches of the PubMed and Web of Science databases (from 1993-2025.03), focusing on high-impact studies on miRNA expression, and their functional mechanisms and clinical utility in gastric precancerous and cancerous lesions. Key Content and Findings: Stage-specific miRNA dysregulation contributes to gastric disease progression. In chronic gastritis (CG), miR-155 and let-7b regulate inflammation, while miR-92a-1-5p and miR-296-5p participate in intestinal metaplasia (IM) by modulating CDX2/FOXD1 and ERK signaling. In gastric cancer (GC), miR-21 and miR-375 regulate proliferation and apoptosis. Clinically, circulating miRNA panels (e.g., miR-4257, miR-6785-5p, and miR-187-5p) enhance early detection, while miR-125a-5p boosts the trastuzumab response via ERBB2 targeting. Despite progress, challenges remain in the mechanistic and clinical validation of miRNAs. Integrating multi-omics and machine learning may optimize miRNA-based diagnostics and therapeutics for precision medicine. Conclusions: This review highlights miRNAs as pivotal regulators in gastric carcinogenesis and promising precision medicine tools. The study findings will promote the standardization of profiling methods and accelerate translational research, both of which are essential to the advancement of GC diagnostic and therapeutic strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.